Allogene Therapeutics (ALLO) Cash & Equivalents (2018 - 2026)

Allogene Therapeutics has reported Cash & Equivalents for 9 years, with the latest figure at $25.1 million in Q1 2026.

• Quarterly Cash & Equivalents fell 40.98% year-over-year to $25.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.1 million (down 40.98% YoY) and the FY2025 annual result came in at $51.7 million, down 31.28% from the prior year.
• Cash & Equivalents fell to $25.1 million in Q1 2026 per ALLO's latest filing, from $51.7 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $161.5 million in Q2 2024 and troughed at $11.8 million in Q4 2022.
• A 5-year average of $71.4 million and a median of $69.2 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents sank 89.85% in 2022, then soared 567.82% in 2023.
• Over 5 years, Cash & Equivalents stood at $11.8 million in 2022, then jumped by 567.82% to $78.5 million in 2023, then retreated by 4.22% to $75.2 million in 2024, then tumbled by 31.28% to $51.7 million in 2025, then tumbled by 51.53% to $25.1 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $25.1 million, $51.7 million, and $37.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.